February 15, 2018 / 12:13 PM / 6 months ago

BRIEF-Protalix Biotherapeutics Announces Final Dosing Of Last Patient In Phase II Clinical Trial Of OPRX-106

Feb 15 (Reuters) - Protalix Biotherapeutics Inc:

* PROTALIX BIOTHERAPEUTICS ANNOUNCES FINAL DOSING OF LAST PATIENT IN PHASE II CLINICAL TRIAL OF OPRX-106 IN PATIENTS WITH ULCERATIVE COLITIS

* PROTALIX BIOTHERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE RESULTS FROM PHASE II CLINICAL STUDY OF OPRX-106 BY END OF MARCH 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below